Supplemental Table S3 from Spatial Transcriptomic Analysis of Ovarian Cancer Precursors Reveals Reactivation of IGFBP2 during Pathogenesis

Supplemental Table S3 from Spatial Transcriptomic Analysis of Ovarian Cancer Precursors Reveals Reactivation of IGFBP2 during Pathogenesis

<p>Raw data provided by Nanostring bioinformatic team</p>

保存先:

書誌詳細
第一著者:	Yeh Wang (14964041) (author)
その他の著者:	Peng Huang (14964044) (author), Brant G. Wang (14964047) (author), Tricia Murdock (14964050) (author), Leslie Cope (14964053) (author), Fang-Chi Hsu (14964056) (author), Tian-Li Wang (14964059) (author), Ie-Ming Shih (14964062) (author)
出版事項:	2025
主題:	Cancer Cancer Risk Factors Cancer Biology Tumor Biology Molecular and Cellular Biology Cancer Detection and Diagnosis Cancer Prevention Biomarkers Early detection biomarkers Cancer Interception Biomarkers and intervention Carcinogenesis Tumor initiation and promotion Epigenetics DNA methylation Gynecological Cancers Ovarian cancer Tumor Evolution
タグ:	タグ追加タグなし, このレコードへの初めてのタグを付けませんか!

類似資料

Supplemental Table S4 from Spatial Transcriptomic Analysis of Ovarian Cancer Precursors Reveals Reactivation of IGFBP2 during Pathogenesis
著者:: Yeh Wang (14964041)
出版事項: (2025)

Supplementary Table S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
著者:: Raphaël Leman (17314506)
出版事項: (2025)

Supplementary Table S2 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
著者:: Raphaël Leman (17314506)
出版事項: (2025)

Supplementary Table S3 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
著者:: Raphaël Leman (17314506)
出版事項: (2025)

Supplementary Table S4 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
著者:: Raphaël Leman (17314506)
出版事項: (2025)

Supplementary Table S5 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
著者:: Raphaël Leman (17314506)
出版事項: (2025)

Supplementary Table S6 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
著者:: Raphaël Leman (17314506)
出版事項: (2025)

Figure 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
著者:: Nicola S. Meagher (15048462)
出版事項: (2025)

Figure 2 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
著者:: Nicola S. Meagher (15048462)
出版事項: (2025)

Figure 3 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
著者:: Nicola S. Meagher (15048462)
出版事項: (2025)

Table 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
著者:: Nicola S. Meagher (15048462)
出版事項: (2025)

Table 2 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
著者:: Nicola S. Meagher (15048462)
出版事項: (2025)

Table 3 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
著者:: Nicola S. Meagher (15048462)
出版事項: (2025)

Supplementary Tables S1-S11 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
著者:: Nicola S. Meagher (15048462)
出版事項: (2025)

Supplemental Table S3 from Clonal Hematopoiesis in Young Women Treated for Breast Cancer
著者:: Christopher J. Gibson (15907642)
出版事項: (2025)

Supplemental Table S4 from Clonal Hematopoiesis in Young Women Treated for Breast Cancer
著者:: Christopher J. Gibson (15907642)
出版事項: (2025)

Supplementary Figure S7 from <i>NPY</i> Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
著者:: Katleen Janssens (15053356)
出版事項: (2025)

Supplementary Table S2 from Clinical Relevance of <i>BRCA1</i> Promoter Methylation Testing in Patients with Ovarian Cancer
著者:: Félix Blanc-Durand (15049400)
出版事項: (2025)

Supplementary Table 4: SpatialDecon derived immune cell counts from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
著者:: Colin S. Wood (15293247)
出版事項: (2025)

Supplementary Table S3 from Circulating Exosomal PD-L1 at Initial Diagnosis Predicts Outcome and Survival of Patients with Osteosarcoma
著者:: Jun Wang (15051911)
出版事項: (2025)

Figure 1 from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
著者:: Colin S. Wood (15293247)
出版事項: (2025)

Figure 2 from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
著者:: Colin S. Wood (15293247)
出版事項: (2025)

Figure 3 from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
著者:: Colin S. Wood (15293247)
出版事項: (2025)

Figure 4 from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
著者:: Colin S. Wood (15293247)
出版事項: (2025)

Figure 5 from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
著者:: Colin S. Wood (15293247)
出版事項: (2025)

Figure 6 from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
著者:: Colin S. Wood (15293247)
出版事項: (2025)

Table 1 from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
著者:: Colin S. Wood (15293247)
出版事項: (2025)

Supplementary Table S1 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
著者:: Sanna Pikkusaari (15055802)
出版事項: (2025)

Supplementary Table S2 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
著者:: Sanna Pikkusaari (15055802)
出版事項: (2025)

Supplementry Table 3: REACTOME Gene Set Enrichment Analysis results from Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases
著者:: Colin S. Wood (15293247)
出版事項: (2025)

Figure 1 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
著者:: James R. Larkin (14936324)
出版事項: (2025)

Figure 2 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
著者:: James R. Larkin (14936324)
出版事項: (2025)

Figure 3 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
著者:: James R. Larkin (14936324)
出版事項: (2025)

Figure 4 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
著者:: James R. Larkin (14936324)
出版事項: (2025)

Figure 5 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
著者:: James R. Larkin (14936324)
出版事項: (2025)

Table 1 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
著者:: James R. Larkin (14936324)
出版事項: (2025)

Supplementary Table S1 from Additional Oncogenic Alterations in <i>RAS</i>-Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes
著者:: Athanasios Bikas (16006076)
出版事項: (2025)

Supplementary figures and tables FTS1 from Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial
著者:: Daniel S. Green (15047598)
出版事項: (2025)

Supplementary file 3: Supplementary Tables. from circFNDC3B Accelerates Vasculature Formation and Metastasis in Oral Squamous Cell Carcinoma
著者:: Xiang Li (15386727)
出版事項: (2025)

Supplementary Video from Shortwave Infrared Imaging Enables High-Contrast Fluorescence-Guided Surgery in Neuroblastoma
著者:: Laura Privitera (16015972)
出版事項: (2025)

Cannot write session to /tmp/vufind_sessions/sess_k5vj28im6tr7qsjf02aqrun7ns